Luke S. Myers

Luke S. Myers

Auto-generated profile, based on publicly available information

Luke S. Myers

Department of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
SDScott V. Dindot
Scott V. Dindot
SCSarah Christian
Sarah Christian
William MurphyWilliam Murphy
William Murphy
ABAllyson Berent
Allyson Berent
JPJennifer Panagoulias
Jennifer Panagoulias
JSJill Silverman
Jill Silverman
Angelman syndrome is a devastating neurogenetic disorder for which there is currently no effective treatment. It is caused by mutations or epimutations affecting the expression or function of the maternally inherited allele of the ubiquitin-protein ligase E3A ( UBE3A ) gene. The paternal UBE3A allele is imprinted in neurons of the central nervous system (CNS) by the UBE3A antisense ( UBE3A-AS ) transcript, which represents the distal end of the small nucleolar host gene 14 ( SNHG14 ) transcription unit. Reactivating the expression of the paternal UBE3A allele in the CNS has long been pursued as a therapeutic option for Angelman syndrome. Here, we described the development of an antisense oligonucleotide (ASO) therapy for Angelman syndrome that targets an evolutionarily conserved region demarcating the start of the UBE3A-AS transcript. We designed and chemically optimized gapmer ASOs targeting specific sequences at the start of the human UBE3A-AS transcript. We showed that ASOs targeting this region precisely and efficiently repress the transcription of UBE3A-AS , reactivating the expression of the paternal UBE3A allele in neurotypical and Angelman syndrome induced pluripotent stem cell–derived neurons. We further showed that human-targeted ASOs administered to the CNS of cynomolgus macaques by lumbar intrathecal injection repress UBE3A-AS and reactivate the expression of the paternal UBE3A allele throughout the CNS. These findings support the advancement of this investigational molecular therapy for Angelman syndrome into clinical development ( ClinicalTrials.gov , NCT04259281).

21 July 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
LMLuke S. Myers
Luke S. Myers
SCSarah G. Christian
Sarah G. Christian
SSSean Simpson
Sean Simpson
RSRenan Sper
Renan Sper
CTClint Taylor
Clint Taylor
SDScott V. Dindot
Scott V. Dindot
Angelman syndrome is a neurodevelopmental disorder characterized by severe motor and cognitive deficits. It is caused by the loss of the maternally inherited allele of the imprinted ubiquitin-protein ligase E3A ( UBE3A ) gene. Rodent models of Angelman syndrome do not fully recapitulate all the symptoms associated with the condition and are limited as a preclinical model for therapeutic development. Here, we show that pigs ( Sus scrofa ) with a maternally inherited deletion of UBE3A ( UBE3A -/+ ) have altered postnatal behaviors, impaired vocalizations, reduced brain growth, motor incoordination, and ataxia. Neonatal UBE3A -/+ pigs exhibited several symptoms observed in infants with Angelman syndrome, including hypotonia, suckling deficits, and failure to thrive. Collectively, these findings are consistent with the pathophysiology and developmental trajectory observed in individuals with Angelman syndrome. We anticipate that this pig model will advance our understanding of the pathophysiology of Angelman syndrome and be used as a preclinical large animal model for therapeutic development.

9 December 2024 in Current Protocols
Verified
Journal Article
Closed access
LMLuke S. Myers
Luke S. Myers
SCSarah Christian
Sarah Christian
JFJennifer Fridley
Jennifer Fridley
SDScott V. Dindot
Scott V. Dindot

24 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
LMLuke S. Myers
Luke S. Myers
TMTanner G. Monk
Tanner G. Monk
LMLuis A. Martinez
Luis A. Martinez
ATAlasdair J. Taylor
Alasdair J. Taylor
SCSarah G. Christian
Sarah G. Christian
SDScott V. Dindot
Scott V. Dindot
Angelman syndrome is a neurodevelopmental disorder caused by loss of the maternally inherited UBE3A allele and is characterized by severe cognitive, motor, and communication impairments. Increased delta (1– 4 Hz) activity on electroencephalogram (EEG) assessed by visual inspection and by spectral power analysis is a robust feature of the disorder in humans and rodent models and is used as a biomarker of Angelman syndrome. This aspect of the phenotype has not been evaluated in the recently developed pig model of Angelman syndrome. Here, we analyzed scalp EEG recordings from freely moving pigs carrying a maternal UBE3A deletion ( UBE3A -/+ ) across three age groups to determine whether they recapitulate the delta power abnormalities characteristic of the disorder. UBE3A -/+ pigs exhibited elevated delta power during both wakefulness and sleep compared with wild-type littermates, with the largest differences observed during the awake state. The typical increase in delta power that accompanies the transition from wakefulness to sleep was also reduced in UBE3A -/+ pigs. These effects were observed across study groups, demonstrating that the maternal UBE3A -deletion pig model reproduces the elevated delta power EEG phenotype of Angelman syndrome. Our results establish noninvasive scalp EEG as a translationally relevant tool for assessing neural dysfunction in this large-animal model and provide a framework for preclinical therapeutic testing. This work strengthens the utility of the pig model for mechanistic studies and therapeutic development in Angelman syndrome.

11 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
LMLuke S. Myers
Luke S. Myers
SCSarah G. Christian
Sarah G. Christian
SSSean Simpson
Sean Simpson
RSRenan Sper
Renan Sper
CTClint Taylor
Clint Taylor
SDScott V. Dindot
Scott V. Dindot
Angelman syndrome is a neurodevelopmental disorder characterized by severe motor and cognitive deficits. It is caused by the loss of the maternally inherited allele of the imprinted ubiquitin-protein ligase E3A ( UBE3A ) gene. Rodent models of Angelman syndrome do not fully recapitulate all the symptoms associated with the condition and are limited as a preclinical model for therapeutic development. Here, we show that pigs ( Sus scrofa ) with a maternally inherited deletion of UBE3A ( UBE3A −/+ ) have altered postnatal behaviors, impaired vocalizations, reduced brain growth, motor incoordination, and ataxia. Neonatal UBE3A −/+ pigs exhibited several symptoms observed in infants with Angelman syndrome, including hypotonia, suckling deficits, and failure to thrive. Collectively, these findings are consistent with the pathophysiology and developmental trajectory observed in individuals with Angelman syndrome. We anticipate that this pig model will advance our understanding of the pathophysiology of Angelman syndrome and be used as a preclinical large animal model for therapeutic development.

22 October 2025 in bioRxiv
Verified
Preprint
Open access
LMLuke S. Myers
Luke S. Myers
JGJohn F. Griffin
John F. Griffin
SCSarah G. Christian
Sarah G. Christian
SDScott V. Dindot
Scott V. Dindot
There is a growing need for alternative animal models to test brain-targeted therapies, and pigs are emerging as a promising option. Their utility, however, depends on reliable estimations of central nervous system (CNS) tissue and cerebrospinal fluid (CSF) volumes, which are essential for translating therapeutic doses between studies in animals and humans. To address this need, we conducted a cross-sectional study of 12 commercial pigs ( Sus scrofa ) across four age groups (2, 5, 11, and 19 weeks). High-resolution magnetic resonance images (MRI) of the brain and spinal cord were acquired using T2-weighted turbo spin echo with fat saturation and short tau inversion recovery scans. CNS tissue and CSF volumes were segmented and quantified using 3D Slicer, along with additional anatomical measurements. Our findings reveal notable age-related changes, including spinal CSF volume surpassing brain CSF volume in older pigs, highlighting shifts in CSF distribution that may influence dosing and delivery strategies for CNS-targeted therapies. This study provides a reference for future research using pig models in CNS disease studies and underscores the importance of incorporating brain and spinal CSF and CNS volume data into preclinical models.